Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation

The authors thank the ISCIII – Instituto de Salud Carlos III and are grateful for co- funding received from the European Union, FIS (Fondo de Investigación Sanitaria – Spanish Health Research Fund) grants PI21/00896 and FI19/00067; Miguel Servet Program (CP23/00017); CIBER de Enfermedades Respiratorias (CIBERES); BASEAS (Basophils in Eosinophilic Asthma) Study, Study Code ESR 20-20764 AstraZeneca Farmacéutica Spain, S.A.; and FEDER (Fondo Europeo de Desarrollo Regional) funds